Status:
TERMINATED
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
Lead Sponsor:
GlaxoSmithKline
Conditions:
HIV-1
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
For HIV-infected individuals with highly resistant viruses, higher drug levels may be required to block the virus. This study investigates that concept by comparing the efficacy of standard fosamprena...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Multiple protease-inhibitors experienced HIV-1 infected individuals experiencing virological failure and who's virus is not fully resistant to boosted fosamprenavir and boosted lopinavir based on genotypic resistance tests.
- Exclusion criteria:
- No full resistance to FPV/r or LPV/r
- Planned use of NNRTIs as part of the study salvage regimen
- Application of additional exclusion criteria as determined by physician.
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00144833
Start Date
March 1 2005
Last Update
November 12 2007
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Clinical Trials Call Center
Darlinghurst, New South Wales, Australia, 2010
2
GSK Clinical Trials Call Center
Carlton, Victoria, Australia, 3053
3
GSK Clinical Trials Call Center
Brussels, Belgium, 1000
4
GSK Clinical Trials Call Center
Vancouver, British Columbia, Canada, V6Z 2C7